Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Carboprost tromethamine

Carboprost tromethamine: 1 brand, 13 generics; first approved Jul 02, 2019; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 13 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
13
Listed patents
0
Presentations
14

Brand (NDA) products

Originator applications
  • NDA 017989—
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP

Generic (ANDA) products (13)

Abbreviated applications
  • CARBOPROST TROMETHAMINE
    ANDA 2195292026
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2180132024
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2159012024
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONDiscontinued—
  • CARBOPROST TROMETHAMINE
    ANDA 2176572023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2168972023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2171982023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2169392023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2168242023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2168822023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2144992022
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2153372022
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2131182021
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP
  • CARBOPROST TROMETHAMINE
    ANDA 2119412019
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 0.25MG BASE/MLINJECTABLEINJECTIONRxAP

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
7 yr 4 mo ago
Most recent approval
4 mo ago

Approvals span 2019–2026 across 14 FDA applications.

Brand (NDA) 17%
Generic (ANDA) 1393%

Carboprost tromethamine: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.